Nessan Bermingham is the founder of Triplet Therapeutics. Triplet Therapeutics has raised $59M in total funding. Latest round: Series A.
Nessan Bermingham, Ph.D. is the co-founder, president, and CEO of Triplet Therapeutics, a biotechnology company focused on developing treatments for repeat expansion disorders. The company launched with $59 million in financing, including a $49 million Series A led by MPM Capital and Pfizer Ventures, and a $10 million seed investment from Atlas Venture. Bermingham has nearly two decades of experience leading life science startups and is also a co-founder of Intellia Therapeutics and Korro Bio.
Full founder directory · Investor directory · Company funding database · Fundraising library